BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

被引：8
|
作者：
Cho, Shih-Feng [1 ,2 ,3 ,4 ]
Anderson, Kenneth C. [1 ,2 ]
Tai, Yu-Tzu [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷
基金：
美国国家卫生研究院;
关键词：
MATURATION ANTIGEN; REMISSIONS; RECEPTORS;
D O I：
10.21037/atm.2018.11.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF ANTI-BCMA CAR T-CELL THERAPY IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA
    Barnes, J., I
    Frosch, Z. A.
    Garfall, A. L.
    Vogl, D.
    Lin, J.
    VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [42] Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis
    Richardson, Tim
    Schuette, Daniel
    Kobbe, Guido
    Baermann, Ben-Niklas
    Holderried, Tobias A. W.
    Schmitz, Friederike
    Crysandt, Martina
    Hallek, Michael
    Scheid, Christoph
    Holtick, Udo
    Cornely, Oliver A.
    Stemler, Jannik
    Mellinghoff, Sibylle C.
    BLOOD ADVANCES, 2025, 9 (06) : 1370 - 1375
  • [43] Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Li, Chunrui
    Zhou, Jianfeng
    Wang, Jue
    Hu, Guang
    Du, Aihua
    Zhou, Xiaoxi
    Meng, Li
    Hong, Zhenya
    Chen, Liting
    Mao, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Development of KITE-585: A Fully Human Anti-BCMA CAR T-Cell Therapy for the Treatment of Multiple Myeloma
    Adams, Gregor B.
    Feng, Jun
    Ghogha, Atefeh
    Mardiros, Armen
    Murakami, Jodi
    Phung, Tammy
    Rodriguez, Ruben
    Sievers, Stuart
    Spindler, Tassja J.
    Wiltzius, Jed
    Yarka, Clare
    Yoder, Sean C.
    Polverino, Tony
    MOLECULAR THERAPY, 2017, 25 (05) : 133 - 133
  • [45] Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy
    Subramanian, Naveen G.
    Pleitez, Hector Garcia
    Pasvolsky, Oren
    Kalariya, Nilesh
    Patel, Krina K.
    Ferreri, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] γ-SECRETASE INHIBITORS IMPROVE MULTIPLE MYELOMA BCMA CAR-T THERAPY
    不详
    CANCER DISCOVERY, 2019, 9 (11) : 1483 - 1483
  • [47] CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
    Mishra, Abhinava K.
    Gupta, Ashna
    Dagar, Gunjan
    Das, Dayasagar
    Chakraborty, Abhijit
    Haque, Shabirul
    Prasad, Chandra Prakash
    Singh, Archana
    Bhat, Ajaz A.
    Macha, Muzafar A.
    Benali, Moez
    Saini, Kamal S.
    Previs, Rebecca Ann
    Saini, Deepak
    Saha, Dwaipayan
    Dutta, Preyangsee
    Bhatnagar, Aseem Rai
    Darswal, Mrinalini
    Shankar, Abhishek
    Singh, Mayank
    VACCINES, 2023, 11 (11)
  • [48] Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy
    Ababneh, Hazim S.
    Yee, Andrew J.
    Raje, Noopur S.
    Martin, Sidney
    Frigault, Matthew J.
    Ng, Andrea K.
    Patel, Chirayu G.
    RADIOTHERAPY AND ONCOLOGY, 2023, 189
  • [49] Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
    Wachsmann, Tassilo L. A.
    Meeuwsen, Miranda H.
    Remst, Dennis F. G.
    Buchner, Karen
    Wouters, Anne K.
    Hagedoorn, Renate S.
    Falkenburg, J. H. Frederik
    Heemskerk, Mirjam H. M.
    BLOOD ADVANCES, 2023, 7 (20) : 6178 - 6183
  • [50] CAR T cell therapy for multiple myeloma
    Barranco, Caroline
    NATURE CANCER, 2023, 4 (12) : 1644 - 1644
12345